Journal of Clinical Endocrinology & Metabolism, Vol 62, 379-383, Copyright © 1986 by Endocrine Society

ARTICLES

Low serum osteocalcin levels in glucocorticoid-treated asthmatics

IR Reid, GE Chapman, TR Fraser, AD Davies, AS Surus, J Meyer, NL Huq and HK Ibbertson

Serum osteocalcin (OC) levels were measured in 19 asthmatic patients receiving long term glucocorticoid therapy and in age- and sex-matched asthmatic patients not receiving this treatment. In the glucocorticoid- treated patients, the mean OC level was approximately 50% less than that in the control group (P less than 0.001), and there was a direct correlation between serum OC and 1,25-dihydroxyvitamin D [1,25-(OH)2D; r = 0.71; P less than 0.001]. Multiple regression analysis in a total of 39 glucocorticoid-treated patients indicated that OC correlated directly to 1,25-(OH)2D and inversely to glucocorticoid dose. There was no correlation between OC and 1,25-(OH)2D in the control group and no significant difference in mean serum 1,25-(OH)2D between the steroid- treated asthmatic patients and the asthmatic control patients. The effect of a 4-day course of oral 1,25-(OH)2D on serum OC was studied in six patients with glucocorticoid excess and six normal subjects. There was a similar percent increase in OC levels in both groups, though the basal concentrations and absolute increases were substantially less in the steroid-treated group. It is likely that the depression of serum OC in glucocorticoid-treated patients results from the reduction in the rate of bone formation induced by these hormones.

This article has been cited by other articles:

				K. H. Baek, W. Y. Lee, K. W. Oh, H. S. Kim, J. H. Han, M. I. Kang, B. Y. Cha, K. W. Lee, H. Y. Son, S. K. Kang, et al. Changes in the Serum Growth Factors and Osteoprotegerin after Bone Marrow Transplantation: Impact on Bone and Mineral Metabolism J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1246 - 1254. [Abstract] [Full Text] [PDF]

				B. Dawson-Hughes Bone Loss Accompanying Medical Therapies N. Engl. J. Med., September 27, 2001; 345(13): 989 - 991. [Full Text] [PDF]

				E. Stacey, P. Korkia, M. V. J. Hukkanen, J. M. Polak, and O. M. Rutherford Decreased Nitric Oxide Levels and Bone Turnover in Amenorrheic Athletes with Spinal Osteopenia J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3056 - 3061. [Abstract] [Full Text]

				I. R. Reid Glucocorticoid Effects on Bone J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1860 - 1862. [Full Text]

				I. Chiodini, V. Carnevale, M. Torlontano, S. Fusilli, G. Guglielmi, M. Pileri, S. Modoni, A. Di Giorgio, A. Liuzzi, S. Minisola, et al. Alterations of Bone Turnover and Bone Mass at Different Skeletal Sites due to Pure Glucocorticoid Excess: Study in Eumenorrheic Patients with Cushing's Syndrome J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1863 - 1867. [Abstract] [Full Text]

				J. B. Lian, V. Shalhoub, F. Aslam, B. Frenkel, J. Green, M. Hamrah, G. S. Stein, and J. L. Stein Species-Specific Glucocorticoid and 1,25-Dihydroxyvitamin D Responsiveness in Mouse MC3T3-E1 Osteoblasts: Dexamethasone Inhibits Osteoblast Differentiation and Vitamin D Down-Regulates Osteocalcin Gene Expression Endocrinology, May 1, 1997; 138(5): 2117 - 2127. [Abstract] [Full Text] [PDF]

				N. G. Arvidson, B. Gudbjörnsson, A. Larsson, and R. Hällgren The timing of glucocorticoid administration in rheumatoid arthritis Ann Rheum Dis, January 1, 1997; 56(1): 27 - 31. [Abstract] [Full Text]

				P. Sambrook, J. Birmingham, P. Kelly, S. Kempler, T. Nguyen, N. Pocock, and J. Eisman Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin N. Engl. J. Med., June 17, 1993; 328(24): 1747 - 1752. [Abstract] [Full Text]

				N. Morrison, J Shine, J. Fragonas, V Verkest, M. McMenemy, and J. Eisman 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene Science, December 1, 1989; 246(4934): 1158 - 1161. [Abstract] [PDF]